scholarly journals Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical Trials

2016 ◽  
Vol 7 (3) ◽  
pp. 283-288 ◽  
Author(s):  
T. G. Murali Dhar ◽  
Hai-Yun Xiao ◽  
Jenny Xie ◽  
Lois D. Lehman-McKeeman ◽  
Dauh-Rurng Wu ◽  
...  
Keyword(s):  
Clinical Trials ◽  
S1p1 Receptor ◽  
Receptor Modulator ◽  
Preclinical Pharmacology

scholarly journals 6 Efficacy of cenerimod, a selective S1P1 receptor modulator, in the MRL/lpr mouse model of systemic lupus erythematosus

2019 ◽  
Author(s):  
Marianne M Martinic ◽  
Sylvie Froidevaux ◽  
Estelle Gerossier-Creusat ◽  
Enrico Vezzali ◽  
Anna Stalder ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Mouse Model ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
S1p1 Receptor ◽  
Receptor Modulator

Preclinical pharmacology of FL442, a novel nonsteroidal androgen receptor modulator

2014 ◽  
Vol 387 (1-2) ◽  
pp. 8-18 ◽  
Author(s):  
Pekka K. Poutiainen ◽  
Tuulia Huhtala ◽  
Tiina Jääskeläinen ◽  
Aleksanteri Petsalo ◽  
Jenni Küblbeck ◽  
...  
Keyword(s):  
Androgen Receptor ◽  
Receptor Modulator ◽  
Preclinical Pharmacology

scholarly journals Pharmacokinetics, Pharmacodynamics, Tolerability, and Food Effect of Cenerimod, a Selective S1P1 Receptor Modulator in Healthy Subjects

2017 ◽  
Vol 18 (12) ◽  
pp. 2636 ◽  
Author(s):  
Pierre-Eric Juif ◽  
Daniela Baldoni ◽  
Maribel Reyes ◽  
Darren Wilbraham ◽  
Salvatore Febbraro ◽  
...  
Keyword(s):  
Healthy Subjects ◽  
Food Effect ◽  
S1p1 Receptor ◽  
Receptor Modulator

Modeling the Effect of the Selective S1P1 Receptor Modulator Ponesimod on Subsets of Blood Lymphocytes

2016 ◽  
Vol 34 (3) ◽  
pp. 599-609 ◽  
Author(s):  
Dominik Lott ◽  
Andreas Krause ◽  
Christian A. Seemayer ◽  
Daniel S. Strasser ◽  
Jasper Dingemanse ◽  
...  
Keyword(s):  
Blood Lymphocytes ◽  
S1p1 Receptor ◽  
Receptor Modulator

scholarly journals Recent advances in the medical treatment of breast cancer

F1000Research ◽  
2016 ◽  
Vol 5 ◽  
pp. 2786 ◽  
Author(s):  
Daniel A. Vorobiof
Keyword(s):  
Breast Cancer ◽  
Clinical Trials ◽  
Medical Treatment ◽  
Breast Cancer Treatment ◽  
Chemotherapeutic Drugs ◽  
Therapeutic Approaches ◽  
The Past ◽  
New Therapeutic Approaches ◽  
Receptor Modulator ◽  
Medical Oncologists

Over the past few decades, the systemic therapy of breast cancer (early and advanced) has changed considerably. For the past 40–50 years, and since the discovery and further therapeutic use of tamoxifen, a selective estrogen receptor modulator, breast cancer treatment has become the model for the development and success of tailored medical treatment. Much still needs to be done in improving outcomes for all patients with breast cancer, and especially for those who have advanced breast cancer, a challenging area for medical oncologists. Ongoing international clinical trials are currently evaluating new therapeutic approaches and identifying specific biological subsets that could determine a patient’s ability to respond to particular chemotherapeutic drugs.

scholarly journals Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion

PLoS ONE ◽  
2018 ◽  
Vol 13 (2) ◽  
pp. e0193380 ◽  
Author(s):  
Krister Bamberg ◽  
Ulrika Johansson ◽  
Karl Edman ◽  
Lena William-Olsson ◽  
Susanna Myhre ◽  
...  
Keyword(s):  
Mineralocorticoid Receptor ◽  
Electrolyte Excretion ◽  
Organ Protection ◽  
Receptor Modulator ◽  
Preclinical Pharmacology
Sign in / Sign up

Export Citation Format

Share Document